Mazor Robotics (NASDAQ: MZOR) and Presbia (NASDAQ:LENS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.
Insider and Institutional Ownership
26.4% of Mazor Robotics shares are held by institutional investors. Comparatively, 16.1% of Presbia shares are held by institutional investors. 74.7% of Presbia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a breakdown of recent ratings for Mazor Robotics and Presbia, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Mazor Robotics currently has a consensus target price of $39.60, suggesting a potential downside of 23.26%. Presbia has a consensus target price of $9.67, suggesting a potential upside of 155.73%. Given Presbia’s stronger consensus rating and higher probable upside, analysts clearly believe Presbia is more favorable than Mazor Robotics.
This table compares Mazor Robotics and Presbia’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Mazor Robotics and Presbia’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mazor Robotics||$36.38 million||36.20||-$18.66 million||($0.71)||-72.68|
Presbia has lower revenue, but higher earnings than Mazor Robotics. Mazor Robotics is trading at a lower price-to-earnings ratio than Presbia, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Mazor Robotics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Presbia has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500.
Presbia beats Mazor Robotics on 8 of the 14 factors compared between the two stocks.
About Mazor Robotics
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications. Its Renaissance System and its predecessor are used in a number of spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement augmentations. Furthermore the Company developed the Renaissance Brain Module, an application of its Renaissance System that provides control over the insertion of surgical instruments during brain surgery.
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company’s lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company’s solution is a standalone solution for plano presbyopes, or those individuals suffering from presbyopia but do not have any other visual disorders.
Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with MarketBeat.com's FREE daily email newsletter.